If there is no overall survival benefit in metastatic breast cancer: Does it imply lack of efficacy? Taxanes as an example

Birgit E. P. J. Vriens, Dorien J. A. Lobbezoo, Joep P. J. de Hoon, Jurgen Veeck, Adri C. Voogd, Vivianne C. G. Tjan-Heijnen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)189-198
JournalCancer Treatment Reviews
Volume39
Issue number2
DOIs
Publication statusPublished - Apr 2013

Keywords

  • Breast cancer
  • Chemotherapy
  • Taxanes
  • Docetaxel
  • Paclitaxel

Cite this